[
    [
        {
            "time": "2023-01-15",
            "original_text": "礼来、豪森长效GLP-1医保价流出！国采后原研落选药品也降价了",
            "features": {
                "keywords": [
                    "GLP-1",
                    "医保价",
                    "国采",
                    "原研药",
                    "降价"
                ],
                "sentiment_score": -0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "礼来、豪森长效GLP-1医保价流出！国采后原研落选药品也降价了",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-01-15",
            "original_text": "人民金融·创新药指数涨0.28% | 国内首款CAR-T要来了，4款获突破性治疗认证，中国CAR-T疗法将迎突破",
            "features": {
                "keywords": [
                    "创新药指数",
                    "CAR-T",
                    "突破性治疗",
                    "疗法突破"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "人民金融·创新药指数涨0.28% | 国内首款CAR-T要来了，4款获突破性治疗认证，中国CAR-T疗法将迎突破",
                "Correlation": 7,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-01-15",
            "original_text": "恒瑞医药(600276.SH)子公司获2个药物临床试验批准通知书",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "临床试验",
                    "批准通知书"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "恒瑞医药(600276.SH)子公司获2个药物临床试验批准通知书",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-01-15",
            "original_text": "恒瑞医药(600276.SH)：贝伐珠单抗注射液及SHR-1701注射液获准临床试验",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "贝伐珠单抗",
                    "SHR-1701",
                    "临床试验"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "恒瑞医药(600276.SH)：贝伐珠单抗注射液及SHR-1701注射液获准临床试验",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-01-15",
            "original_text": "恒瑞医药：贝伐珠单抗注射液及SHR-1701注射液临床试验获批准",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "贝伐珠单抗",
                    "SHR-1701",
                    "临床试验"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "恒瑞医药：贝伐珠单抗注射液及SHR-1701注射液临床试验获批准",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-01-15",
            "original_text": "医药生物行业：Q4医药板块延续恢复态势 结构性机会突出",
            "features": {
                "keywords": [
                    "医药生物",
                    "Q4",
                    "恢复态势",
                    "结构性机会"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物行业：Q4医药板块延续恢复态势 结构性机会突出",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 8,
                "Entity_Density": 4,
                "Market_Scope": 10,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-01-15",
            "original_text": "北向资金高比例持有股票名单",
            "features": {
                "keywords": [
                    "北向资金",
                    "高比例持有"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "全市场"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "北向资金高比例持有股票名单",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-01-13",
            "original_text": "A股融资融券日报：两融余额增加15.74亿元（1月13日）",
            "features": {
                "keywords": [
                    "A股",
                    "融资融券",
                    "两融余额",
                    "增加"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "全市场"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "A股融资融券日报：两融余额增加15.74亿元（1月13日）",
                "Correlation": 4,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 2,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 6
            }
        },
        {
            "time": "2023-01-15",
            "original_text": "北向资金动向盘点：电子脱颖而出",
            "features": {
                "keywords": [
                    "北向资金",
                    "电子",
                    "动向"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "电子"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "北向资金动向盘点：电子脱颖而出",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        }
    ]
]